Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen
July 07, 2014 10:15 ET
|
Genmab A/S
Company Announcement
Genmab to receive USD 25 million milestone payment from Janssen
Milestone triggered by progress in the Phase III study of daratumumab in combination with lenalidomide...
GSK og Genmab modtager EU markedsføringstilladelse for Arzerra™ (ofatumumab) som førstelinjebehandling af CLL i kombination med chlorambucil eller bendamustin til patienter, som ikke er egnede til fludarabin-baseret behandling
July 03, 2014 09:15 ET
|
Genmab A/S
Selskabsmeddelelse
Arzerra godkendt til brug i EU som førstelinjebehandling af CLL i kombination med chlorambucil eller bendamustin til patienter, som ikke er egnede til fludarabin-baseret...
GSK and Genmab Receive EU Authorization for Arzerra™ (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy
July 03, 2014 09:15 ET
|
Genmab A/S
Company Announcement
Arzerra approved for use in EU as first-line treatment for CLL in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based...
GSK og Genmab offentliggør top-line resultater fra et fase III studie med ofatumumab over for lægens valg til behandling af bulky fludarabin-refraktært CLL
June 27, 2014 14:08 ET
|
Genmab A/S
Selskabsmeddelelse
Studiet nåede ikke det primære endpoint som var progressionsfri overlevelse
Data vil blive yderligere analyseret de kommende måneder
London, Storbritannien og...
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL
June 27, 2014 14:08 ET
|
Genmab A/S
Company Announcement
Trial did not meet the primary endpoint of Progression Free Survival
Data to be further analyzed in the coming months
Copenhagen, Denmark; June 27, 2014 –...
Selskabsvedtægter for Genmab A/S
June 16, 2014 08:56 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 12. juni 2014 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Articles of Association for Genmab A/S
June 16, 2014 08:56 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated June 12, 2014. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel Curtis...
Tildeling af warrants til medarbejdere i Genmab
June 12, 2014 11:51 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 12. juni 2014 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at på et bestyrelsesmøde har bestyrelsen besluttet at tildele 17.000 warrants (tegningsoptioner)...
Grant of Warrants to Genmab Employees
June 12, 2014 11:51 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; June 12, 2014 – Genmab A/S (OMX: GEN) announced today that at a board meeting the board decided to issue 17,000 warrants to employees of the company as...
Genmab Announces DuoBody and HexaBody Platform Collaboration with Undisclosed Biotechnology Company
June 04, 2014 02:18 ET
|
Genmab A/S
Company Announcement
Research collaboration with an undisclosed large Biotechnology company for DuoBody® and HexaBody™ technology platforms
Genmab’s first HexaBody...